HSD11B1 Intron 3 — The Tissue Cortisol Switch
Your adrenal glands release cortisone, an inactive form of cortisol, into the bloodstream.
Inside tissues — particularly liver, adipose tissue, and brain — the enzyme 11beta-hydroxysteroid
dehydrogenase type 1 (11beta-HSD1, encoded by HSD11B1) converts cortisone back into active
cortisol | the primary stress glucocorticoid, with wide effects on glucose, fat, and immune function.
This local amplification means that intracellular cortisol concentrations in fat and liver can
substantially exceed plasma levels — a separate, tissue-controlled glucocorticoid environment.
The rs12086634 variant sits in an enhancer element in intron 3 | a non-coding regulatory region
that boosts transcription of the nearby gene of HSD11B1
and modulates how much enzyme is produced. Because the G allele reduces transcription in vitro,
carriers produce less 11beta-HSD1 and regenerate less cortisol locally, while the common T allele
(especially TT homozygotes combined with the rs846910 A allele) is linked to higher enzyme
expression and activity.
The Mechanism
The intron 3 enhancer region of HSD11B1 responds to tissue-specific transcription factors.
In vitro reporter assays show that the G allele reduces transcriptional activity | Draper et al.
J Clin Endocrinol Metab 2006 compared to the common T
allele. Less enzyme means less cortisone-to-cortisol conversion in adipose tissue and liver.
The downstream consequences run in two directions: (1) lower local glucocorticoid activity may
reduce visceral fat deposition and insulin resistance risk — hence the G allele's protective
signal in some populations; (2) the corresponding higher cortisol clearance (more cortisol excreted
as cortisone) triggers the HPA axis to compensate, increasing ACTH-driven adrenal output and
paradoxically raising adrenal androgen production in susceptible individuals.
The enzyme relies on NADPH provided by hexose-6-phosphate dehydrogenase (H6PD) | H6PD acts
as the luminal NADPH generator; mutations in H6PD cause cortisone reductase deficiency
in the endoplasmic reticulum lumen. Reduced HSD11B1 expression shifts the enzyme's net
directionality away from cortisol regeneration toward cortisone formation.
The Evidence
A study of 102 Caucasian PCOS patients vs 98 controls | Draper et al. J Clin Endocrinol
Metab 2006 found the G allele associated with
PCOS status (P = 0.041), driven entirely by lean patients (P = 0.025). G allele carriers
had lower morning plasma cortisol and higher ACTH-stimulated cortisol response | suggesting
enhanced cortisol clearance with compensatory HPA activation,
elevated DHEA-S, and — notably — lower LDL cholesterol, consistent with reduced glucocorticoid
activity in the liver. These findings suggest the G allele may confer metabolic protection while
simultaneously predisposing lean women to adrenal hyperandrogenism.
A larger study of 600 women with and without PCOS | Gambineri et al. Eur J Endocrinol 2011
found that the TT genotype at rs12086634 combined with the rs846910 A allele (GA/TT haplotype)
was associated with metabolic syndrome at OR 2.77 (95% CI 1.16–6.67), P = 0.023,
regardless of PCOS diagnosis. Women with this haplotype had higher HSD11B1 mRNA in adipose tissue
and a significantly elevated cortisol regeneration rate (16.1 ± 0.7 vs 12.1 ± 1.1 nmol/min, P = 0.044).
This positions the T allele (not G) as the risk allele for metabolic syndrome in the context
of the combined haplotype.
In 616 South Indian subjects | Velmurugan et al. Endocr Connect 2017,
the TG genotype (one G copy) contributed to increased risk of both type 2 diabetes (OR 1.91;
95% CI 1.33–2.76, P = 0.0005) and metabolic syndrome (OR 2.37; 95% CI 1.39–4.05, P = 0.0015),
and was associated with elevated systolic blood pressure compared to TT controls. This contrasts
with some European studies and underscores the population-dependent complexity of these associations.
A systematic review | Torchen et al. Int J Diabetes Dev Ctries 2015
concluded that HSD11B1 variants play only a small role in most populations, with stronger
associations in Indian and Pima Indian cohorts, and largely null findings in East Asian
and French-Canadian populations.
Separately, HSD11B1 polymorphisms in intron 5 | Stavrou et al. Osteoporos Int 2009
were significantly associated with femoral neck bone mineral density (P = 0.00005) and
vertebral fracture risk in 1,329 postmenopausal women, consistent with the known role of
local glucocorticoid excess in suppressing osteoblast activity and promoting adipogenic
differentiation of bone marrow progenitor cells.
Practical Implications
For people carrying the G allele (GT or GG), the likely effect is modestly reduced 11beta-HSD1
activity — meaning less local cortisol regeneration in fat and liver. This may offer metabolic
protection (lower visceral fat accumulation tendency) but at the cost of higher HPA axis
activity. For TT homozygotes, particularly those who also carry the rs846910 A allele, the
evidence points toward elevated tissue cortisol regeneration, which manifests as higher metabolic
syndrome risk, elevated fasting glucose, and in women, a tendency toward visceral fat accumulation.
Monitoring fasting glucose and waist circumference is particularly relevant for TT homozygotes.
Compounds that reduce 11beta-HSD1 activity — including liquorice-derived carbenoxolone | a
non-selective 11beta-HSD inhibitor studied in clinical trials,
and dietary patterns that lower cortisol burden — have been explored as strategies but are not
yet clinically actionable for this specific variant. Selective 11beta-HSD1 inhibitors remain
in pharmaceutical development.
For bone health, the broader HSD11B1 data on fracture risk and BMD suggests that individuals
with high local glucocorticoid activity (likely TT carriers with elevated enzyme expression)
should prioritize bone density monitoring as they age.
Interactions
The functionally important interaction is with rs846910 in the HSD11B1 promoter region.
The Gambineri 2011 study demonstrates that the combined GA (rs846910) + TT (rs12086634) haplotype
is the high-activity combination: together they elevate HSD11B1 mRNA expression and cortisol
regeneration rate in adipose tissue, with OR 2.77 for metabolic syndrome. Single-SNP analyses
of either variant alone show weaker effects. This is a classic gene-gene interaction within the
same gene — the two regulatory variants appear to act additively on transcriptional output.
Compound interaction proposal: Individuals carrying rs846910 GA genotype AND rs12086634 TT
genotype both have an approximately 2.8-fold elevated metabolic syndrome risk and higher adipose
cortisol regeneration. The combined recommendation for this haplotype: monitor fasting glucose,
insulin, and waist circumference annually, and consider time-restricted eating patterns that
minimize cortisol-mediated postprandial insulin surges. Both individual variant recommendations
are subsumed by this combined finding.
All Genotypes
One G allele modestly reduces local cortisol regeneration; elevated metabolic risk seen in some populations
You carry one copy of the rs12086634 G allele (about 32% of people globally). One G allele partially reduces HSD11B1 expression compared to TT, placing your tissue cortisol regeneration in an intermediate range. In South Indian cohorts, the TG genotype was associated with meaningful increases in type 2 diabetes risk (OR 1.91) and metabolic syndrome risk (OR 2.37) compared to TT, along with elevated systolic blood pressure. This finding may reflect population-specific effects or interactions with other genetic and dietary factors. European studies have been less consistent. Overall, the GT genotype warrants proactive glucose and metabolic monitoring.
Two copies of the G allele substantially reduce local cortisol regeneration from cortisone
You carry two copies of the rs12086634 G allele, which is found in approximately 4% of people of European ancestry. The G allele reduces HSD11B1 transcriptional activity in vitro, meaning your tissues — particularly liver and adipose — produce less 11beta-HSD1 enzyme and regenerate less active cortisol from inactive cortisone. This is associated with lower local glucocorticoid activity and may reduce your tendency toward visceral fat accumulation and metabolic syndrome driven by cortisol excess. However, the lower tissue cortisol creates a compensatory HPA axis response: your pituitary releases more ACTH, which drives higher adrenal cortisol and androgen output. Studies in lean PCOS women show G allele carriers have higher DHEA-S and elevated adrenal responsiveness.
Two T alleles support higher HSD11B1 expression, increasing local cortisol regeneration and metabolic syndrome risk
You carry two copies of the common T allele, present in approximately 64% of people. The TT genotype is associated with the highest HSD11B1 expression and 11beta-HSD1 enzyme activity, particularly when co-occurring with the rs846910 A allele. Studies in Southern European women show TT homozygotes combined with the rs846910 A allele have a 2.77-fold elevated metabolic syndrome risk, higher adipose tissue HSD11B1 mRNA, and an elevated cortisol regeneration rate (16.1 vs 12.1 nmol/min). Elevated local cortisol in fat and liver promotes visceral adiposity, hepatic glucose output, and insulin resistance — collectively the metabolic syndrome phenotype. Bone health may also be affected through glucocorticoid-mediated suppression of osteoblast activity.